

APTUS PHARMA LIMITED

Date: 30th October 2026

To,
The BSE Ltd
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400001

SECURITY CODE: 544529

SCRIPT SYMBOL: APPL

Subject: Intimation under Regulation 30 of SEBI (LODR) Regulations, 2015 – Receipt of In-Principle Approval for Preferential Issue

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that BSE Limited, vide its letter bearing reference no. LOD/PREF/HC/FIP/1040/2026-27 dated October 30, 2026, has granted its in-principle approval under Regulation 28(1) of the SEBI (LODR) Regulations, 2015, for the proposed preferential issue of equity shares of the Company, as approved by the shareholders at their Annual General Meeting held on September 14, 2026.

A copy of the in-principle approval letter received from BSE Limited is enclosed herewith for your information and records.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For Aptus Pharma Limited

Hathi Tejash
Maheshchandra
ndra

Digitally signed by
Hathi Tejash
Maheshchandra
Date: 2026.10.30
19:16:11 +05'30'

Tejash Hathi
Managing Director
DIN: 03151221

Regd. Address: Ashutosh Buildcon, Opp. Slok – 2, Nr. Harikrupa Logistic Park, Aslali, Daskroi,
Ahmedabad, Gujarat – 382427, India

Contact: 76004 27827, E-mail: aptuspharma@rediffmail.com, Website: www.aptus-pharma.com
CIN: U24230GJ2010PLC061957, GSTIN: 24AAICA7890D1ZM

October 30, 2026

LOD/PREF/HC/FIP/1040/2026-27

To,
The Company Secretary,
Aptus Pharma Ltd.
Ashutosh Buildcon, Opp. Slok - 2,
Nr. Harikrupa Logistic Park, Aslali,
Daskroi, Ahmedabad,
Gujarat- 382427.

Re: In-principle' approval under Regulation 28(1) of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Dear Sir/Madam,

We refer to your application seeking our **"In-principal approval for the issue of 15,99,270 equity shares of Rs.10/- each at price not less than Rs.280/- each to promoters and non- promoters on preferential basis"**.

The Exchange hereby grants its 'in-principle' approval for the aforesaid issue. This 'in-principle' approval should not be construed as our approval for listing of aforesaid security, and you are required to duly and separately comply with the requirements in respect thereof.

You are advised to ensure that the issue and allotment of securities is strictly in accordance with the provisions of the Companies Act, 2013, Securities Contracts (Regulation) Act, 1956, the Securities and Exchange Board of India Act, 1992, the Depositories Act, 1996 including the Rules, Regulations, Guidelines, etc. made there under, Chapter V of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (ICDR Regulations), the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 (LODR Regulations) and the Listing Agreement signed with us. In addition, you shall also obtain such statutory and other approvals as are required for the purpose.

Further, the company is advised to strengthen internal controls (to monitor trades being executed by the proposed allottees in the scrip of the company) before allotment of securities in order to avoid any non-compliances in respect of trades being executed by the allottees in contravention to provisions of Chapter V of SEBI (ICDR) Regulations. In this regard,

- a) Company is advised to obtain an undertaking from the allottee(s) confirming that they shall not do intra-day trading in the scrip of the company or any sale in the scrip of the company till the allotment date of the security as required under SEBI (ICDR) Regulations.



- b) The company may note that the responsibility/onus is solely on the Issuer company to verify the above (a) and ensure compliance with applicable provisions including Regulation 167(6) of SEBI ICDR regulations, 2018.
- c) The company may also note that any non-compliances, if observed by the exchanges post the undertaking and verification by the Issuer company may impact the listing of such shares.

On allotment of securities pursuant to this 'in principle' approval you are required to make a listing application without delay, with applicable fees, in terms of Regulation 14 of the LODR Regulations and comply with the post issue formalities.

Listing application and the checklist for post issue listing formalities can be downloaded from the link: <https://www.bseindia.com/static/about/downloads.aspx>. Further, it should be noted by Depositories and the Company that in case of allotment of Convertible Securities, there would be automatic release of excess lock-in period of Pre-Preferential Holding of allottees by Depositories in compliance with SEBI(ICDR) Regulations, 2018 without requirement of any NOC by the Exchange.

In addition to above, the company should note that as per Schedule XIX – Para (2) of ICDR Regulations and as specified in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023, "the issuer or the issuing company, as the case may be, shall, make an application for listing, **within twenty days** from the date of allotment, to one or more recognized stock exchange(s)" along with the documents specified by stock exchange(s) from time to time. Any Non-compliance with the above requirement will attract, the fine as mentioned in SEBI circular no. SEBI/HO/CFD/PoD-2/P/CIR/2023/00094 dated June 21, 2023.

The Exchange reserves its right to withdraw this 'in-principle' approval at any stage if the information submitted to the Exchange is found to be incomplete/ incorrect/ misleading/ false or if it contravenes any Rules, Bye-laws and Regulations of the Exchange, LODR Regulations, ICDR Regulations and Guidelines/ Regulations issued by any statutory authorities etc.

Yours faithfully,



Nitinkumar Pujari
Assistant Vice President



Hetika Chandni
Deputy Manager